Humira Sales Will Get Modest Bump From Medicare Part D, Abbott Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm is seeking additional indications which could create an additional $1-$2 bil. in incremental sales beyond the TNF inhibitor’s RA base.
You may also be interested in...
Abbott's Humira Approved For Psoriatic Arthritis, First-Line Rheumatoid Arthritis
Abbott will support dedicated sales representatives to detail Humira to dermatologists following psoriatic arthritis approval.
Celgene To Submit Revlimid Phase III Special Protocol Assessment For CLL To FDA Shortly
Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.
AstraZeneca Continues Pipeline Expansion Via Two Licensing Deals Totaling $800 Million
Agreements expand the firm’s position in the COPD space, while also entering obesity, diabetes and metabolic syndrome space.